BioCentury
ARTICLE | Company News

Amgen, Alantos, Ilypsa deal

June 11, 2007 7:00 AM UTC

AMGN will acquire Alantos and Ilypsa. AMGN will acquire Alantos for $300 million in cash. Alantos' lead compound is ALS 2-0426, which is in Phase IIa testing to treat Type II diabetes. Servier (Neuilly-sur-Seine, France) has rights to the small molecule inhibitor of dipeptidyl peptidase-4 (DPP-4) outside the U.S. (see BioCentury, Oct. 30, 2006). AMGN also plans to develop Alantos' preclinical matrix metalloproteinase (MMP) inhibitors to treat osteoarthritis. The deal is expected to close next quarter. ...